

Appendix 4 :

Number of missing data across studies concerning HBA1c array taking on consideration completed studies (shaded boxes). Relates the real levels of LOCF imputation

	Duration of placebo comparison	Number of subjects	Baseline (J-21 - J1)	Week 12 (J56- J105)	Week 18 (J98 - J147)	Week 26 (J154 - J203)	Week 52 (J337 - J386)
			NA (%)	NA (%)	NA (%)	NA (%)	NA (%)
Study 1	12	386	11 (2.8)	50 (13)	382 (99)	386 (100)	386 (100)
Study 2	18	279	1 (0.4)	21 (7.5)	25 (9)	278 (99.6)	279 (100)
Study 3	52	469	2 (0.4)	40 (8.5)	53 (11.3)	84 (17.9)	156 (33.3)
Study 4	52	269	0 (0)	13 (4.8)	22 (8.2)	35 (13)	62 (23)
Study 5	26	678	4 (0.6)	50 (7.4)	65 (9.6)	93 (13.7)	678 (100)
Study 6	26	918	3 (0.3)	50 (5.4)	81 (8.8)	118 (12.9)	918 (100)
Study 7	> 52	4330	28 (0.6)	287 (6.6)	342 (7.9)	454 (10.5)	704 (16.3)
Study 8	26	716	6 (0.8)	46 (6.4)	63 (8.8)	84 (11.7)	137 (19.1)
Study 9	26	342	2 (0.6)	18 (5.3)	30 (8.8)	40 (11.7)	342 (100)
Study 10	18	676	1 (0.1)	23 (3.4)	26 (3.8)	672 (99.4)	676 (100)
Study 11	> 52	5813	2 (0)	332 (5.7)	4963 (85.4)	439 (7.6)	700 (12)
Study 12	26	218	1 (0.5)	24 (11)	203 (93.1)	43 (19.7)	218 (100)
Total		15094	61 (0.4)	954 (6.3)	6255 (41.4)	2726 (18.1)	5256 (34.8)